– Ampersand Capital Partners has closed its latest fund, Ampersand 2026 (AMP-26) Limited Partnership, with $1.5 billion in limited partner commitments.
– AMP-26 was oversubscribed and is Ampersand’s 12th primary fund since 1992.
– The fund achieved a single close at its hard cap in less than five months after launch.
– AMP-26 received strong support from a diversified global investor base, including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices.
– Managing Partner Herb Hooper thanked both existing and new investors for their confidence in Ampersand’s specialized investment strategy.
– Ampersand’s strategy focuses on partnering with founders and management teams to build market-leading companies that provide mission-critical tools and services to the healthcare and life sciences innovation ecosystem.
– For more than 35 years, Ampersand has partnered with founders and CEOs to accelerate growth and build leading companies across its core healthcare sectors.
– Through AMP-26, the firm will continue making both majority and minority investments in healthcare and life sciences companies.
– Ampersand targets companies with revenues between $10 million and $200 million and positive EBITDA.
– The new fund will support Ampersand’s continued focus on backing entrepreneurs and scaling market-leading businesses within its core sectors.
